Dermatitis data underwhelm, but Amgen sees possible ‘practice-changing’ asset for myasthenia gravis

ARTICLE | Product Development

Uplizna’s Phase III data in myasthenia gravis impress; rocatinlimab’s results less strong but a new MoA may still have a play in atopic dermatitis

By Lauren Martz, Director of Biopharma Intelligence, and Paul Bonanos, Director of Biopharma Intelligence

September 25, 2024 12:56 AM UTC

In a pair of readouts announced late Tuesday, Amgen said its Phase III results from Uplizna could be “practice-changing” for myasthenia gravis patients, while its first late-stage data from anti-OX40 receptor antibody rocatinlimab in atopic dermatitis suggested an uphill climb for the program, and raise the question of whether targeting OX40 ligand may be more effective than targeting the receptor.

The better result for Amgen Inc. (NASDAQ:AMGN) came from the Phase III MINT study. The big biotech’s CD19-targeting antibody Uplizna inelibizumab led to a 1.9-point placebo-adjusted improvement in disease scores at week 26, meeting the trial’s primary endpoint…